GenomeDx Announces Results From New Validation Study for Decipher Prostate Cancer Classifier

GenomeDx Announces Results From New Validation Study for Decipher Prostate Cancer Classifier
shutterstock_77211889GenomeDx Biosciences has announced its data presented at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) shows significant evidence of the capacity of the Decipher® Prostate Cancer Classifier to predict which patients may benefit from radiotherapy after prostate surgery. The Decipher® Prostate Cancer Classifier is an experimental device that by assessing the activity of multiple genomic markers associated with metastatic disease, can directly measure a patient’s biological risk of developing metastatic prostate cancer. In a study titled “Validation of a genomic classifier for predicting metastasis following post-operative radiation therapy in high-risk prostate cancer,” presented at the ASTRO meeting, the results from a validation study of Decipher use in 188 patients from Thomas Jefferson University and Mayo Clinic who underwent prostate surgery between 1990 and 2009 was demonstrated. The results showed that Decipher improved diagnostic value, allowing a clear distinction between those at high risk of metastasis when compared to other available clinical tools. The researchers observed that 42.5% of patients classified as average and high-risk according to the CAPRA-S scores (a commonly used ris
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *